These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 16998791)

  • 1. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
    Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
    Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
    Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
    Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
    Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
    Buffone A; Capalbo C; Ricevuto E; Sidoni T; Ottini L; Falchetti M; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Breast Cancer Res Treat; 2007 Dec; 106(2):289-96. PubMed ID: 17333342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
    Perkowska M; BroZek I; Wysocka B; Haraldsson K; Sandberg T; Johansson U; Sellberg G; Borg A; Limon J
    Hum Mutat; 2003 May; 21(5):553-4. PubMed ID: 12673801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.